Blue Wolf Capital, a private equity firm, agreed to acquire seven manufacturing and development facilities from Recipharm, a contract development and manufacturing organization. Financial terms were not disclosed. “We are delighted that Blue Wolf has committed to acquire seven of our OSD sites, marking a significant step for both organizations. I am confident that Blue Wolf will continue to elevate service excellence and bolster the organization for the benefit of customers and patients. By consolidating our site network, we are sharpening our focus on New Chemical Entities (NCEs), medium to high potency drugs, and on-patent medications within the oral solid dosage sector. This strategic divestment aligns with our overarching vision to emerge as the premier choice CDMO for both our customers and patients. I extend my best wishes to all our colleagues embarking on this new journey at those seven sites," Greg Behar, Recipharm CEO.